ZMYM3 S464: a potential phospho-regulatory hub in epigenetic remodeling and oncogenesis

Area of Science:

• Cancer Biology
• Epigenetics
• Molecular Oncology

Background:

• Dysregulated epigenetic control and DNA repair defects are implicated in cancer and neurodevelopmental disorders.
• ZMYM3, a chromatin protein, influences histone deacetylation, homologous recombination (HR), and cytoskeleton organization.
• The post-translational regulation of ZMYM3 activity is largely uncharacterized.

Purpose of the Study:

• To define the regulatory landscape of ZMYM3, focusing on the S464 phosphosite.
• To investigate the role of ZMYM3 S464 phosphorylation in cancer, particularly in relation to HR deficiency.

Main Methods:

• Integration of global phosphoproteomics data to map ZMYM3 regulatory networks.
• Analysis of upstream kinases and interacting proteins associated with ZMYM3 S464 phosphorylation.
• Bioinformatic analysis (cProSite) of patient tumor data to assess S464 phosphorylation patterns in cancer.

Main Results:

• The S464 phosphosite in ZMYM3's zinc-finger domain is frequently detected and co-regulated with kinases (CDK13, HIPK1, CDK9, CLK3) and interactors (BRCA1, HDAC6, SWI/SNF).
• Phosphorylated networks involving ZMYM3 S464 are enriched in chromatin remodeling, DNA damage response, and cytoskeletal dynamics.
• S464 hyper-phosphorylation is observed in breast and ovarian cancers, correlating with HR-deficiency signatures.

Conclusions:

• ZMYM3 S464 acts as a phospho-regulatory hub coordinating epigenetic silencing, HR repair, and mitotic fidelity.
• Cancer-specific upregulation of ZMYM3 S464 suggests its potential as a biomarker for HR-deficiency stratification.
• ZMYM3 S464 represents a therapeutic target for modulating BRCA1 function or epigenetic drug sensitivity in cancer.